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Obesity has been considered a risk factor for osteoarthritis and it is usually accepted that obesity contributes to the development
and progression of osteoarthritis by increasing mechanical load of the joints. Nevertheless, recent advances in the physiology
of white adipose tissue evidenced that fat cells produce a plethora of factors, called adipokines, which have a critical role in the
development of ostearthritis, besides to mechanical effects. In this paper, we review the role of adipokines and highlight the cellular
and molecular mechanisms at play in osteoarthritis elicited by adipokines. We also emphasize how defining the role of adipokines
has broadned our understanding of the diversity of factors involved in the genesis and progression of osteoarthritis in the hope of
modifying it to prevent and treat diseases.
1. Introduction
Osteoarthritis (OA) is a multifactorial joint degenerative
disease characterized by deep alteration of articular cartilage,
changes in subchondral bone, osteophyte formation, and
synovial inflammation. It is the most common arthritis,
but its etiology is largely unknown. Age, obesity, sex, and
previous injury are considered as significant risk factors.
Although OA is commonly described as noninflammatory
disease, inflammation is recognized as contributing to the
symptoms and progression of OA [1, 2]. Inflammation may
be either a primary event in OA or secondary to other
aspects of disease such as biochemical changes within the
cartilage. Obesity is also considered as a risk “of weight”
in the pathogenesis of OA, and its contribution may be
due to different convergent mechanisms that lead, as final
result, to cartilage destruction, being a mechanical stress
surely a risk factor for weight bearing joints [3, 4]. However,
several studies demonstrated that obesity is also a risk
factor for nonweight-bearing joints [5]. Obesity is nowadays
considered as a chronic low-grade inflammatory status which
is closely related to the release, by white adipose tissue, of
a plethora of factors, most of them of proinflammatory
nature, including classical cytokines such as IL-6, IL-1 and
TNF-α, as well as adipokines, such as leptin, adiponectin,
resistin, visfatin, and other recently identified factors such
as chemerin, lipocalin, or serum Amiloyd 3 (SAA3) [6–8].
Adipokines are a growing family of WAT-produced factor
that exert pleiotropic functions through several pathways
and are involved in a wide spectrum of activities including
not only glucose and lipid metabolism but also modulation
of immune and inflammatory response [9]. So, certain
adipokines, can be viewed as potential factors that hub obe-
sity, inflammation, and arthritis (Figure 1). This paper will
address the most relevant findings regarding the involvement
of several adipokines, namely, leptin, adiponectin, resistin,
visfatin, and others, in osteoarthritis.
2. Leptin
Leptin is a 16 kDa nonglcosylated hormone that is encoded
by the obese (ob) gene, the murine homolog of human LEP
gene [10]. Leptin exerts its biological actions through the
activation of its OB-Rb long-form receptor isoform which
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Figure 1: Schematic representation of the complex network that links white adipose tissue dysfunction, bone, and cartilage tissues.
Dysfunctional fat produces an excess of proinflammatory adipokines that are able to interact with bone cells, synovial cells, and chondrocytes
by inducing proinflammatory mediators (cytokines, ROS, NO) and cartilage degradative factors (metalloproteases and ADAMTSs).
is encoded by the gene diabetes (db) and belongs to the
class 1 cytokine receptor superfamily. It is mainly produced
by adipocytes, and its circulating levels are correlated with
white adipose tissue (WAT)mass. Mutation in either ob gene,
or the gene encoding the leptin receptor (the diabetes, or
db gene), results in severe obesity. This hormone decreases
food intake and increases energy consumption by acting on
specific hypothalamic nuclei, inducing anorexigenic factors
as cocaine amphetamine related transcript (CART) and
suppressing orexigenic neuropeptides such as neuropeptide
Y [11]. Leptin levels are mostly dependent on the amount of
body fat, but its synthesis is also regulated by inflammatory
mediators [12].
It is increasingly evident that this hormone plays a key
role in the OA pathophysiology. Some initial findings have
suggested an anabolic role of this hormone in the cartilage.
Leptin expression is much higher in osteoarthritic human
cartilage than in normal cartilage. The intra-articular injec-
tion of leptin can strongly stimulate the synthesis of insulin-
like growth factor-1 (IGF-1) and transforming growth
factor-β (TGF-β) at both the messenger RNA (mRNA) and
protein levels which can exert anabolic activities in cartilage
metabolism [13]. Leptin concentrations in synovial fluid
were also significantly correlated with BMI in people with
severe osteoarthritis [13]. These findings have suggested that
high circulating leptin levels in obese individuals may protect
cartilage from osteoarthritic degeneration.
Nevertheless, Otero et al. have demonstrated that, in
cultured human and murine chondrocytes, type 2 nitric
oxide synthase (NOS2) is synergistically activated by the
combination of leptin plus interferon-γ, and NOS2 acti-
vation by IL-1β is increased by leptin via a mechanism
involving JAK2, PI3K, and mitogen activated kinases (MEK1
and p38) [14, 15]. Nitric oxide (NO), which is induced
by a wide range of proinflammatory cytokines, is a well-
known proinflammatory mediator on joint cartilage, where
it triggers chondrocyte phenotype loss, apoptosis, and met-
alloproteinases (MMPs) activation.
Recently, it has been demonstrated that leptin is able to
induce also the expression of MMPs involved in OA cartilage
damage, such as MMP-9 and MMP-13 [16]. Furthermore
evidences suggested that leptin alone and in combination
with IL-1β upregulates MMP-1 and MMP-3 production
in human OA cartilage through the transcription factor
NF-κB, protein kinase C, and MAP kinase pathways. This
adipokine is also correlated positively to MMP-1 and MMP-
3 in synovial fluid (SF) from OA patients [17]. Noteworthy,
very recently, leptin has been demonstrated to increase IL-
8 production in human chondrocytes [18]. Bao et al. have
defined that leptin enhanced both gene and protein levels
of catabolic factors such as MMP-2 y and MMP-9, while
downregulated the anabolic factors such as basic FGF in
articular cartilage of rats. Additionally, the gene expression of
ADAMTS-4 and -5 were markedly increased and a depletion
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of proteoglycan in articular cartilage was observed after
treatment with leptin. [19].
Leptin also could contribute to abnormal osteoblast
function in OA. In fact, the elevated production of leptin
in OA abnormal subchondral osteoblast is correlated with
the increased levels of ALP (alkaline phosphatase), OC
(osteocalcin), collagen type I, and TGF-β1 (transforming
growth factor β1) inducing a dysregulation of osteoblast
function [20]
Leptin and leptin’s receptor (Ob-Rb) expression levels
were significantly increased in advanced OA cartilage and
in SF. The induction by leptin of IL-1β production, MMP-
9, and MMP-13 protein expression in chondrocytes indicate
a proinflammatory and catabolic role of this hormone on
cartilage metabolism [21].
Ku et al. have demonstrated a relation of SF leptin
concentrations with the radiographic severity of OA in OA
patients, suggesting a role of leptin as an effective marker for
OA [22].
These results suggested that leptin may act as a proin-
flammatory factor on cartilage metabolism, suggesting a
prominent catabolic effect in OA joints. In recent studies,
comparing the incidence of knee osteoarthritis between
ob/ob and db/db mice and controls, no significant differences
have been detected [23].
This recent finding suggested that obesity, per se, is not
a sufficient condition to induce knee OA, but that leptin is
necessary in the pathophysiology of OA development and
progression associated with obesity.
In fact, most studies support the role of the adipokines
as a nonmechanical link between obesity and OA. In
patients with clinical knee osteoarthritis, Berry et al. have
demonstrated that leptin was significantly associated with
increased levels of the bone formation biomarkers, such as
osteocalcin and PINP, and reduced cartilage volume loss. On
the contrary, baseline expression of leptin receptors OB-Rb
was associated with reduced levels of the cartilage formation
biomarkers PIIANP and osteocalcin, with increased cartilage
defects score, and with increased cartilage volume loss [24].
All these results were independent of age, sex, and body mass
index.
However, in another recent published paper, no associa-
tion between leptin levels and hand OA progression has been
demonstrated [25].
3. Adiponectin
Adiponectin, also known as GBP28, apM1, Acrp30, or
AdipoQ, is a 244-residue protein that is produced mainly by
WAT. Adiponectin has structural homology with collagens
VIII and X and complement factor C1q, and it circulates in
the blood in relatively large amounts in different molecular
forms [26, 27].
It increases fatty acid oxidation and reduces the synthesis
of glucose in the liver. Ablation of the adiponectin gene has
no dramatic effect on knockout mice on a normal diet, but
when placed on a high fat/sucrose diet, they develop severe
insulin resistance and exhibit lipid accumulation in muscles.
Circulating adiponectin levels tend to be low in morbidly
obese patients and increase with weight loss [26, 27].
Adiponectin acts via two receptors, one (AdipoR1) found
predominantly in skeletal muscle and the other (AdipoR2) in
liver. Transduction of the adiponectin signal by AdipoR1 and
AdipoR2 involves the activation of AMPK, PPAR-α, PPAR-γ,
and other signalling molecules [27].
Actually, some evidences indicate that adiponectin has
a wide range of effects in pathologies with inflammatory
component, such as cardiovascular disease, endothelial dys-
function, type 2 diabetes, metabolic syndrome, and OA [28].
In contrast to its previously described protective role in
vascular diseases, there are some evidences that adiponectin
might act as a proinflammatory factor in joints, and it could
be involved in matrix degradation.
Adiponectin-treated chondrocytes lead to the induction
of NOS2, via a signalling pathway that involves PI3 kinase.
Similarly, this adipokine also increases IL-6, MMP-3, MMP-
9, and MCP-1 production in the same cell type [29].
Very recently, the induction of MMP-3 by adiponectin in
chondrocytes was further confirmed, and it occurred, in part,
through p38, AMPK, and NF-κB [30]. In addition, Kang et
al. have reported that collagenase-cleaved type II collagen
neoepitope, a product of collagen type II degradation,
was increased in supernatants of adiponectin-induced OA
cartilage explants [31]. Furthermore, it has been reported
that adiponectin is able to induce the expression of IL-6 in
human synovial fibroblasts [32].
Very recently, Frommer and colleagues confirmed the
proinflammatory role of adiponectin in RA. These authors
demonstrated that adiponectin induces gene expression
and protein synthesis of chemokines and proinflammatory
cytokines in RA effector cells, such as synovial fibroblasts,
lymphocytes, chondrocytes, and endothelial cells. In fact,
adiponectin promoted inflammation through cytokine syn-
thesis, attraction of inflammatory cells to the synovium,
and recruitment of prodestructive cells via chemokines, thus
promoting matrix destruction at sites of cartilage invasion
[33].
Filkova et al. found higher adiponectin serum levels in
erosive OA patients compared with nonerosive OA patients
[34]. In the same way, Distel and colleagues have shown that
there was an increase in IL-6 and adiponectin production
in infrapatellar fat pad in knee osteoarthritis [35]. Taken
together, these results suggest that adiponectin may be
considered a potential molecule involved in joint disorders
and matrix degradation.
However, the role of adiponectin in OA is controversial.
There are certain evidences that show an inhibition of IL-
1β-induced MMP-13 expression and upregulation of tissue
inhibitor of metallopreoteinase-2 (TIMP-2) mediated by
adiponectin in chondrocytes [36]. Moreover, in STR/Ort
mice, an animal osteoarthritis model, the serum adiponectin
levels are lower compared with control group [37], suggest-
ing a protective role for this adipokine in the development of
the disease.
To note, clinical data also support the fact that adiponect-
in could be a protective molecule against OA. A very recent
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study developed by Honsawek and Chayanupatkul showed
an inverse correlation between adiponectin and disease
severity [38]. Moreover, it has been reported that patients
with high adiponectin levels had a decreased risk for hand
OA progression, suggesting that this adipokine may be a
protective hormone against cartilage damage [25].
4. Visfatin
Visfatin, also called PBEF (pre-B-cell colony-enhancing fac-
tor) and Nampt (nicotinamide phosphoribosyltransferase),
is a protein of approximately 471 amino acids and 52 kDa
[39]. It is a hormone that originally was discovered in liver,
bone marrow, and muscle, but it is also secreted by visceral
fat [39, 40].
It has been reported that visfatin is increased in obesity.
Moreover, leucocytes from obese patients produce higher
amounts of visfatin compared with lean subjects, and specif-
ically, granulocytes and monocytes are the major producing
cells [41, 42]. Macrophages have been described as a source
for visfatin production too [43].
It is supposed that visfatin has insulin mimetic proper-
ties, however the role of this adipokine in glucosemetabolism
is still unclear [40, 44]. Visfatin is upregulated in models of
acute injury and sepsis [45], and its synthesis is regulated
by other factors such as glucocorticoids, TNF-α, IL-6, and
growth hormone (GH). Moreover, visfatin has been shown
to induce chemotaxis and the production of IL-1β, TNF-α,
and IL-6 in lymphocytes [46].
Recently, Gosset and colleagues have reported that IL-1β
was able to increase visfatin expression in human cultured
chondrocytes [47]. Similarly, visfatin-treated chondrocytes
showed an increase in MMP-3, MMP-13, ADAMTS-4, and
ADAMTS-5 expression, while aggrecan production was
reduced [47], suggesting a prodegradative and catabolic role
of visfatin in articular cartilage.
Another recent study shows that infrapatellar fat pad
from OA patients release high amounts of visfatin [48] and
based on the previous data which suggest that visfatin is able
to induce matrix metalloproteinases, authors concluded that
visfatin secreted by infrapatellar fat pad might contribute to
the pathophysiological changes occurred in OA.
Moreover, Duan and colleagues have reported that OA
patients have increased levels of visfatin in synovial fluid,
and this adipokine is positively correlated with degradation
biomarkers of collagen type II and aggrecan, demonstrating
that visfatin is involved in matrix degradation [49].
5. Resistin
Resistin is a macrophage/monocyte-derived proinflamma-
tory mediator [50]. It belongs to the found in inflammatory
zones (FIZZ) family (also known as RELMs, resistin-like
molecules). It was secreted by adipose tissue, but it has
been found also in macrophages, neutrophils, and other
cell types. Serum resistin levels increase with obesity in
mice, rats, and humans [51, 52]. The proinflammatory
profile of resistin, together with its association with obesity
suggest that this adipokine might be another potential
mediator that links OAwith inflammation and obesity. It was
demonstrated that this adipokine is elevated in both serum
and SF after traumatic joint injuries. Recombinant resistin
stimulated proteoglycan degradation in mouse femoral head
cultures, the induction of inflammatory cytokines, and PGE2
production. Moreover, it inhibited proteoglycan synthesis in
human cartilage explants [53]. However, Go´mez et al. have
not identified an association between baseline serum levels
of resistin and cartilage volume loss [18].
6. Other Adipokines
Chemerin, also known as tazarotene-induced gene 2 and
retinoic acid receptor responder 2 (RARRES2), is a novel
chemoattractant adipokine [54]. It is secreted as an
18 kDa inactive proprotein and activated by posttransla-
tional C-terminal cleavage [55]. Chemerin acts via the G-
coupled receptor chemokine-like receptor 1 (CMKLR1) [54].
Chemerin and its receptor are mainly expressed, but not
exclusively, in adipose tissue [56]. For instance, dendritic cells
and macrophages express chemerin receptor [57]. Moreover,
chondrocytes express chemerin and its receptor [8, 58] and
IL-1β, along with other adipokines and glucocorticoids,
is able to modulate the expression of this adipokine [8],
demonstrating the importance of chemerin in chondrocyte
pathophysiology, being this molecule regulated by others,
which drive inflammatory processes as IL-1β, leptin, LPS,
and so forth.
Lipocalin 2 (LCN2), also termed siderocalin, 24p3,
uterocalin, and neutrophil gelatinase-associated lipocalin, is
a 25 kDa glycoprotein isolated from neutrophil granules,
although adipose tissue is thought to be themain source [59].
The LCN2 protein has been isolated as a 25 kDa monomer,
as a 46 kDa homodimer and in a covalent complex with
MMP-9, and its cellular receptor, megalin (GP330), was
recently described [60]. LCN2 is involved in apoptosis of
haematopoietic cells [61], transport of fatty acids and iron
[62], and modulation of inflammation [63] among other
processes.
LCN2 has recently been identified in chondrocytes
[64]. In these cells IL-1β, leptin, adiponectin, LPS, and
dexamethasone act as potent modulators of its expression
[8]. LCN2 is likely to be involved in matrix degradation since
it forms molecular complexes with MMP-9 [65].
Serum Amyloid A3 (SAA3) protein is an adipokine that
belongs to the family of acute-phase serum amyloid A pro-
teins (A-SAA) secreted in the acute phase of inflammation.
In mice, all A-SAA proteins are actively transcribed [66–68],
whereas in humans, SAA3 is encoded by a pseudogene and
its functional protein is unknown [69, 70].
Mouse SAA3 is involved in metabolic, immune, and
cardiovascular homeostasis [71–73]. It has been reported
that SAA3 is induced in rabbit primary chondrocytes and
it can induce MMP-13 transcription [74]. Furthermore,
very recently SAA3 expression was described in murine
chondrocytes, where it was regulated by cytokines such as IL-
1β, leptin, or adiponectin [8].
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Vaspin is a visceral adipose tissue-derived serpin with
potential antiprotease properties [75]. The administration
of this factor to obese mice improved glucose tolerance and
insulin sensitivity and reversed altered expression of genes
that might promote insulin resistance.
Omentin is a protein of 40 kDa, secreted by omental
adipose tissue and it is highly abundant in human plasma.
Omentin has previously been identified as intelectin, a new
type of Ca2+-dependent lectin. Several studies have shown
that omentin gene expression is alternated by inflammatory
states and obesity [76].
Recently, Sˇenolt et al. have demonstrated increased levels
of vaspin and reduced levels of omentin in the synovial fluid
of patients with RA compared with those with OA [77]. This
finding suggests that these two adipokines are likely involved
in OA pathophysiology.
7. Conclusions
It is now clear that adipokines have multiple relevant roles in
the body, and many research efforts are driven to elucidate
the intricate network among WAT, metabolic disorders,
and inflammatory diseases. Although, many aspects are still
unclear, in this paper we summarize the present knowledge
on the role of adipokines in OA pathophysiology.
However, the present knowledge is almost incomplete
to allow translation of these approaches to clinical practice,
several potential approaches are likely feasible. For instance,
the control of leptin levels by using antibodies in a similar
way to anti-TNF therapy might be an interesting strategy.
Nevertheless, apart from pharmacological perspectives,
it is clear that the main source of all proinflammatory
adipokines is the dysfunctional adipose tissue. Therefore,
reducing fat mass, overeating, and increasing physical activ-
ity remain the essential preventive strategy to counteract the
negative effects of obesity proinflammatory state.
Only further insights that clarify the mechanisms by
adipokines are regulated and which are the concrete roles of
them in the OA pathology, could propose new pharmacolog-
ical approaches for this disease.
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